News for Myomo, Inc. (MYO)

On May 15, 2025, Thomas Kirk, a Director at Myomo Inc, purchased 38,767 shares of the company. Following this transaction, the insider now owns a total of 344,7

On May 12, 2025, Thomas Kirk, a Director at Myomo Inc, purchased 50,000 shares of the company. Following this transaction, the insider now holds a total of 305,

On May 8, 2025, Craig-Hallum analyst Craig Knickerbocker maintained a "Buy" rating on Myomo (MYO) while lowering the price target from $11.00 to $10.00. This up

Myomo, Inc. (NYSE:MYO) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ETCompany ParticipantsTirth Patel - Alliance Advisors, Investor RelationsPaul...

Myomo (MYO) delivered earnings and revenue surprises of 0% and 6.29%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Myomo, Inc. (MYO) launches the MyoPro 2x, enhancing donning, fit, and function for users with upper-limb paralysis. The MyoPro 2x promises improved clin

Transaction Overview On March 12, 2025, Dauntless Investment Group, LLC (Trades, Portfolio) made a strategic move by acquiring 1,999,380 shares of OKYO Pharma L

Massachusetts-based 2seventy bio, Inc. (TSVT), a cell and gene therapy company is up over 76 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Massachusetts-based 2seventy bio, Inc. (TSVT), a cell and gene therapy company is up over 76 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Q4 Revenue: $12.1 million, a 154% increase year-over-year.Full Year Revenue 2024: $32.6 million, up 69% from 2023.Revenue Units Delivered in Q4: 220 units, up

Mar 10, 2025 / 08:30PM GMTOperator Good afternoon, and welcome to the Myomo fourth-quarter 2024 earnings conference call. (Operator Instructions) Please note th

Myomo, Inc. (NYSE:MYO) Q4 2024 Earnings Conference Call March 10, 2025 4:30 PM ETCompany ParticipantsTirth Patel - Alliance Advisors, Investor RelationsPaul...

Myomo (MYO) delivered earnings and revenue surprises of 50% and 24.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Myomo Inc (MYO) is set to release its Q4 2024 earnings on March 10, 2025. The consensus estimate for Q4 2024 revenue is $9.90 million, and the earnings are expe

On February 26, 2025, Dauntless Investment Group, LLC (Trades, Portfolio) made a strategic move by acquiring 108,224 shares of AEON Biopharma Inc. The transacti

Transaction Overview On December 31, 2024, Rosalind Advisors, Inc. (Trades, Portfolio) made a strategic move by acquiring an additional 9,536,647 shares in Biof

**media[538643]**

Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients SHIELD II Enrolled more than 700 Patients

On December 31, 2024, Rosalind Advisors, Inc. (Trades, Portfolio) made a significant move by adding 412,087 shares of OptiNose Inc. (NASDAQ: OPTN) to its portfo